看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
8 k9 Y% r1 L& B& C6 I! }, x, p
& V( D' N- _ ~/ h/ h
! v' G8 w2 E2 OCurrently available feasibility data for possible combination strategies. ! P$ @! G4 j8 ]7 y& z( S5 w
————————————————————————————————
$ P6 B0 R# G3 Q' HCombination Feasibility according to preliminary data
0 z8 U4 C- o$ s/ r—————————————————————————————————— f% {3 h) L9 r. Q Z
Bevacizumab + sorafenib Yes, reduced dose " S- z5 _1 l9 G% [& ?5 |# N( a
Bevacizumab + sunitinib† No 7 t0 d5 k l- O
Bevacizumab + temsirolimus Yes
X- B' B/ _9 l9 V/ ?Bevacizumab + everolimus Yes + `, i# i. r% W
Sorafenib + sunitinib ? . `$ b9 B1 z# ^6 M
Sorafenib + temsirolimus Yes, reduced dose 2 H0 [! B4 }; e7 Y
Sorafenib + everolimus Yes, reduced dose 3 `& S6 }2 n8 ~
Sunitinib + temsirolimus† No
8 \9 r, }, v3 X. B! ?! }8 r: L% A T5 SSunitinib + everolimus ?
& t+ `$ ~4 n/ }8 X2 P% bTemsirolimus + everolimus ? # w: m2 D8 O0 r3 Z; K$ h a/ |
————————————————————
( a: V+ W8 {& J- ]/ m†Led to US FDA warning.' U# Z4 E, ^$ ^% L. b
?: As yet unattempted combination.* m% C# y! ?2 v% M
|